Advertisement

Topics

Evolva SA Company Profile

09:04 EST 11th December 2018 | BioPortfolio

We strive to improve people’s lives by applying our technology and other resources to the discovery and development of new products and processes that benefit the health, well-being and financial economy of patients, consumers and partner companies around the world.

The Company’s primary corporate goal is to build a profitable and sustainable business around its core competencies in compound and pathway discovery and development, and from the commercialisation (by Evolva or its partners) of its product candidates.

We aim to “embed” the results of our technology in products or processes that are partnered with companies and organisations with the expertise and resources to commercialise the products.

Our platform is applicable to a range of industries, including the pharmaceutical, food, chemical and energy sectors. Our main focus is on high value products in the healthcare, nutrition and personal care space.

To achieve this goal the Company intends to employ the following key strategies:

1. Build a balanced portfolio and offset risk

By building a balanced product portfolio, the Company aims to defray risk by increasing the probability of clinical and commercial success and reducing its exposure to the impact of any one product failure. In order to implement this strategy, the Company carries out its own product development programmes, but also plans to partner with third parties in order to defray the cost and risk of clinical development (particularly the cost of late stage clinical trials) and expand marketing power. Although such partnerships may enable the Company to commercialise any approved products without developing its own sales force, the Company may also decide to market approved products on its own in selected indications compatible with its overall resources (e.g., orphan indications, products sold to specialists).

2. Focus on differentiated product candidates that target significant unmet medical needs

We intend to focus on differentiated product candidates that target significant unmet medical needs because they have the potential to provide greater options and choices for the patient or consumer and better pricing potential for the supplier. The Company has chosen to emphasise cardio-renal and infectious disease indications because:

  • together they cause 43% of all deaths in OECD countries, and 51% of all deaths worldwide, and, consequently, are both large markets in which important unmet medical needs remain;
  • compounds created by our technology have similar structural characteristics to natural products, which have an especially strong track record in these sectors;
  • they are especially important segments in emerging pharmaceutical markets such as India and China, and hence are likely to have favourable growth dynamics in the future; and
  • the world’s top 20 pharmaceutical companies are all active in one of these two sectors, providing multiple opportunities to partner.

The Company emphasises small molecule compounds that can be delivered orally. Oral administration is often the most convenient administration route for patients and the most cost-effective for society. In most cases small molecules are also cheaper to manufacture than biologics.

3. Maintain and grow our technology platform

Our proprietary discovery technology platform uses a “disruptive” technological approach to the creation of novel small compounds that differs sharply from the prevailing approaches in the pharmaceutical industry today (i.e., synthetic chemistry and/or protein engineering). As a result, we expect to create compounds with different properties from those discovered by the majority of pharmaceutical companies. We plan to leverage our discovery technology not only to expand its own pipeline, but also to attract third party partners interested in using our technology in their own areas of interest.

4. Maintain and expand discovery and development partnerships

The Company already generates revenues from discovery partnerships with various third parties and plans to maintain and expand its partnerships in both discovery (based primarily on our technology platform) and development (based primarily on our compounds) in the future. The Company sees these partnerships as an important element of its strategy for three main reasons:

  • they help build a balanced portfolio;
  • they provide additional resources and talent; and
  • they could provide us with better understanding of the needs of current and future customers (whether corporations, payors, doctors or patients).

In addition to partnerships in the pharmaceutical sector, we see opportunities to partner in sectors such as bio-defence, pharmaceutical intermediates, industrial chemicals and similar sectors.

Location

Duggingerstrasse 23
Reinach
CH-4153
Switzerland

Contact

Phone: 41 61 485 2000
Fax: 41 61 485 2001
Email: info@evolva.com


News Articles [12 Associated News Articles listed on BioPortfolio]

Evolva announces new CEO

Evolva announces that as part of entering the next phase of its evolution, the current Evolva CEO Simon Waddington steps down as CEO with immediate effect. Until he will leave the company towards the ...

Evolva Holding SA: Aktuelle Geschäftsentwicklung von Evolva

MEDIENMITTEILUNG Aktuelle Geschäftsentwicklung von Evolva 9. November 2018 - Evolva (SIX: EVE) legt heute einen vierteljährlichen Bericht über die aktuelle Geschäftsentwicklung vor, der eine stark...

Evolva (EVE) - Everything EverSweet

Edison Investment Research - Food & Drink - Evolva: Evolva’s Q3 trading statement is mixed, but overall we believe it contains more positive than negative news. The announcement that Cargill and...

Erneuter Chefwechsel bei Evolva - Oliver Walker ersetzt Simon Waddington

(Meldung um weitere Details und Analystenkommentar ausgebaut) Reinach BL (awp) - Nach mehr oder weniger exakt einem Jahr bekommt Evolva erneut einen neuen Chef. Wie das Biotechunternehmen am Dienst...

Evolva bekommt mit Oliver Walker einen neuen CEO

Reinach BL (awp) - Bei Evolva kommt es zu einem Wechsel auf dem Chefsessel. Der bisherige Finanzchef Oliver Walker übernimmt per sofort die Leitung des Biotech-Unternehmens von Simon Waddington. Di.....

Evolva (EVE) - Commercialisation on track

Edison Investment Research - Food & Drink - Evolva: Evolva’s H1 results were in line with expectations and confirm that the current strategy is working to deliver an increased focus on commercia...

Evolva Announces Oliver Walker to Succeed Simon Waddington as CEO

Evolva (SIX: EVE) announces today that, as part of entering the next phase of its evolution, the current Evolva CEO Simon Waddington steps down as CEO with immediate effect. Until...

Evolva on Track to Deliver on Set Targets

Evolva (SIX:EVE) posted its financial results today and provided business highlights for the period from 1 January to 30 June 2018. Highlights ...

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [0 Results]

None

Companies [4 Associated Companies listed on BioPortfolio]

Evolva Holding SA

Evolva’s mission is to discover and provide innovative, sustainable ingredients for health, nutrition and wellness. Evolva uses biosynthetic and evolutionary technologies to ...

Evolva Evolva

Evolva solves the supply chain issues of nature through a 21st century mix of biotechnology and fermentation. We develop, make and sell ingredients that provide significant health...

Evolva SA

We strive to improve people’s lives by applying our technology and other resources to the discovery and development of new products and processes that benefit the health, well-being and financ...

Evolva A/S

We strive to improve people’s lives by applying our technology and other resources to the discovery and development of new products and processes that benefit the health, well-being and financial ec...

More Information about "Evolva SA" on BioPortfolio

We have published hundreds of Evolva SA news stories on BioPortfolio along with dozens of Evolva SA Clinical Trials and PubMed Articles about Evolva SA for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Evolva SA Companies in our database. You can also find out about relevant Evolva SA Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Nutrition
Within medicine, nutrition (the study of food and the effect of its components on the body) has many different roles. Appropriate nutrition can help prevent certain diseases, or treat others. In critically ill patients, artificial feeding by tubes need t...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...


Corporate Database Quicklinks



Searches Linking to this Company Record